The US Food and Drug Administration has yet to update prescribing labels for widely used GLP-1 drugs despite overseas regulators warning of a rare but serious risk of vision loss, highlighting inconsistencies in global safety responses.
The US Food and Drug Administration has left a conspicuous gap in warning language for widely used GLP-1 weight-loss and diabetes medicines, even after flagging a rare but serious form of vision loss as a potential safety issue more than a year ago. As of September 2026, the prescribing information for Ozempic, Wegovy, Rybelsus and Mounjaro still does not mention non-arteritic anterior ischaemic optic neuropathy, or NAION, despite regulatory action overseas.
NAION occurs when blood flow to the optic nerve is interrupted, sometimes causing sudden, often painless sight loss that can be permanent. The issue matters because labels do more than satisfy paperwork: they influence what doctors discuss before prescribing, what pharmacists flag when dispensing, and whether a patient connects a sudden change in vision with a medicine they are taking. In March 2025, the FDA added NAION to its list of potential serious risks for GLP-1 drugs and said it was evaluating whether further action was needed, but its review is still unresolved.
Regulators in other countries have moved faster. The European Medicines Agency said in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and advised patients with sudden or worsening vision problems to contact a doctor without delay. Britain’s Medicines and Healthcare products Regulatory Agency followed in February 2026 with advice urging urgent ophthalmology referral for sudden vision loss. Australia’s Therapeutic Goods Administration went further in July 2026, extending a class-wide warning across GLP-1 medicines and recommending that treatment be stopped if NAION is suspected.
The evidence remains unsettled. Studies have pointed in the same direction, but they have not agreed on the size of the risk, and none of them proves the drugs cause NAION. Diabetes, high blood pressure and sleep apnoea are all risk factors in their own right, which makes it difficult to separate medication effects from background illness. That uncertainty helps explain why regulators have reached different conclusions: European authorities focused on semaglutide, while Australia chose to warn across the whole drug class.
For patients, the practical advice is consistent. Sudden vision loss or blurring in one eye, especially on waking, should be treated as urgent. People should not stop a GLP-1 medicine without speaking to their prescriber, because these drugs can lower blood sugar, reduce weight and improve cardiovascular risk for many users. The FDA has also been weighing other safety questions around the class, including an earlier decision in January 2026 to seek removal of suicidal-behaviour warnings after concluding there was no increased risk in its review.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
